A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD

NCT04498650 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

259

Enrollment

INDUSTRY

Sponsor class

Conditions

Early Alzheimers Disease
Mild Cognitive Impairment Due to AD

Interventions

DRUG: PQ912
DRUG: Placebo

Sponsor

Vivoryon Therapeutics N.V.

Collaborators

[object Object]
[object Object]